Stocktoria
Aurinia Pharmaceuticals Inc. AUPH
Aurinia Pharmaceuticals Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318,000 |
| R&D expense | $32.5M | $20.8M | $49.6M | $45.0M | $51.1M | $50.3M | $52.9M |
| SG&A expense | — | — | $195.0M | $196.4M | $173.5M | $97.3M | $22.3M |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M | -$104.3M | -$90.9M |
| Interest expense | — | — | $2.8M | $0 | $0 | — | — |
| Income tax | -$173.0M | $1.7M | $551,000 | $1.8M | $760,000 | -$94,000 | $144,000 |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M | -$102.7M | -$88.4M |
| EPS (diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-0.95 |
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M | -$69.9M | -$63.6M |
| Cash & equivalents | $80.2M | $83.4M | $48.8M | $94.1M | $231.6M | $272.4M | $306.0M |
| Inventory | $45.7M | $39.2M | $39.7M | $24.8M | $19.3M | $13.9M | $0 |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M | $463.7M | $324.3M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M | $55.9M | $25.7M |
| Shareholders' equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M | $407.8M | $298.6M |
Growth · year-over-year · Revenue CAGR 210.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +20.4% | +34.0% | +31.0% | +193.9% | -9.0% | +15660.4% | — |
| Net income growth | +4893.1% | — | — | — | — | — | — |
| EPS growth | +5075.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.